A 28-year-old agricultural worker is admitted 2 hours after ingesting an organophosphate compound (parathion) in a suicide attempt. He is conscious, alert, with pinpoint pupils, profuse salivation, and bronchial secretions. Respiratory rate is 24/min with mild wheezing. He has received atropine 5 mg IV and shows good response (pupils dilating, secretions drying). What is the most appropriate next step in management?

Explanation

## Clinical Context: Post-Atropine Management The patient has responded well to atropine (pupils dilating, secretions decreasing), indicating successful reversal of **muscarinic** cholinergic excess. The next phase of management requires addressing **nicotinic** effects and preventing enzyme reactivation failure — the role of **pralidoxime (oxime)**. ## Pralidoxime: Timing and Rationale **Key Point:** Pralidoxime is an **acetylcholinesterase reactivator** that works by nucleophilic attack on the phosphorylated enzyme, restoring its function. It is most effective when given **early** (ideally within 24–48 hours, but best within the first 12 hours) before "aging" of the enzyme-phosphate complex occurs. **High-Yield:** Pralidoxime dosing in organophosphate poisoning: - **Loading dose:** 1 g IV bolus over 5–10 minutes - **Maintenance:** 0.5 g/hour IV infusion for 24 hours (or longer if needed) - **Repeat boluses:** 1 g IV every 4–6 hours if signs of cholinergic excess recur **Clinical Pearl:** Pralidoxime is **ineffective against muscarinic effects** (it does not cross the blood–brain barrier well). Therefore, atropine must be given **first** to relieve respiratory distress and other muscarinic manifestations. Once atropine has controlled acute symptoms, pralidoxime is added to: 1. Reactivate acetylcholinesterase and reverse nicotinic effects (muscle weakness, fasciculations, paralysis) 2. Prevent relapse of cholinergic symptoms as atropine is metabolized 3. Reduce the total atropine requirement ## Management Sequence After Atropine Response ```mermaid flowchart TD A[Atropine given, muscarinic signs controlled]:::outcome --> B[Assess nicotinic effects]:::decision B -->|Present or risk of relapse| C[Administer pralidoxime 1 g IV bolus]:::action C --> D[Start pralidoxime infusion 0.5 g/hour]:::action D --> E[Continue for 24 hours or until<br/>cholinesterase recovers]:::action E --> F[Monitor for relapse, repeat atropine<br/>or pralidoxime as needed]:::action B -->|Minimal| G[Still give pralidoxime early<br/>for prevention]:::action G --> F ``` ## Why Pralidoxime Now? **Mnemonic:** **PAM = Pralidoxime After Muscarinic control** — ensures reactivation of acetylcholinesterase and prevents nicotinic relapse. - **Time-sensitive:** Organophosphates cause irreversible phosphorylation of acetylcholinesterase. Pralidoxime can reverse this only before "aging" (typically 24–48 hours, but varies by agent). Parathion ages relatively quickly; early pralidoxime is critical. - **Prevents relapse:** As atropine is metabolized, cholinergic symptoms may recur. Pralidoxime reduces this risk by restoring enzyme function. - **Addresses nicotinic effects:** Muscle weakness, fasciculations, and respiratory muscle paralysis are nicotinic and do not respond to atropine alone. ## Why Not the Other Options? | Option | Why Wrong | |--------|----------| | **Repeat atropine only (B)** | Atropine has already achieved good muscarinic control. Repeating it without pralidoxime delays reactivation of acetylcholinesterase and increases risk of atropine toxicity (tachycardia, hyperthermia, confusion). Pralidoxime must be added now. | | **Gastric lavage + charcoal (C)** | Appropriate for ingested organophosphates but should be done **early** (within 1–2 hours of ingestion) and in parallel with antidote administration, not as a next step after atropine response. At 2 hours post-ingestion with good atropine response, antidote therapy takes priority. | | **Monitor and repeat atropine only on relapse (D)** | Reactive approach that delays pralidoxime and risks relapse of cholinergic symptoms. Pralidoxime should be given **proactively** early in the course to prevent nicotinic manifestations and reduce total atropine requirement. | **Warning:** Do not confuse the sequence: **Atropine first (acute muscarinic crisis) → Pralidoxime second (enzyme reactivation and nicotinic effects) → Supportive care and monitoring (ongoing).** [cite:Park 26e Ch 16; Forensic Medicine & Toxicology (Reddy) Ch 12]